Joanna E Fardell1, Janette Vardy, Ian N Johnston. 1. School of Psychology, The University of Sydney, Australia; Cancer Institute, NSW, Australia. Electronic address: joanna.fardell@sydney.edu.au.
Abstract
AIMS: Previous animal studies have examined the potential for cytostatic drugs to induce learning and memory deficits in laboratory animals but, to date, there is no pre-clinical evidence that taxanes have the potential to cause cognitive impairment. Therefore our aim was to explore the short- and long-term cognitive effects of different dosing schedules of the taxane docetaxel (DTX) on laboratory rodents. MAIN METHODS: Healthy male hooded Wistar rats were treated with DTX (6 mg/kg, 10mg/kg) or physiological saline (control), once a week for 3 weeks (Experiment 1) or once only (10mg/kg; Experiment 2). Cognitive function was assessed using the novel object recognition (NOR) task and spatial water maze (WM) task 1 to 3 weeks after treatment and again 4 months after treatment. KEY FINDINGS: Shortly after DTX treatment, rats perform poorly on NOR regardless of treatment regimen. Treatment with a single injection of 10mg/kg DTX does not appear to induce sustained deficits in object recognition or peripheral neuropathy. SIGNIFICANCE: Overall these findings show that treatment with the taxane DTX in the absence of cancer and other anti-cancer treatments causes cognitive impairment in healthy rodents.
AIMS: Previous animal studies have examined the potential for cytostatic drugs to induce learning and memory deficits in laboratory animals but, to date, there is no pre-clinical evidence that taxanes have the potential to cause cognitive impairment. Therefore our aim was to explore the short- and long-term cognitive effects of different dosing schedules of the taxanedocetaxel (DTX) on laboratory rodents. MAIN METHODS: Healthy male hooded Wistar rats were treated with DTX (6 mg/kg, 10mg/kg) or physiological saline (control), once a week for 3 weeks (Experiment 1) or once only (10mg/kg; Experiment 2). Cognitive function was assessed using the novel object recognition (NOR) task and spatial water maze (WM) task 1 to 3 weeks after treatment and again 4 months after treatment. KEY FINDINGS: Shortly after DTX treatment, rats perform poorly on NOR regardless of treatment regimen. Treatment with a single injection of 10mg/kg DTX does not appear to induce sustained deficits in object recognition or peripheral neuropathy. SIGNIFICANCE: Overall these findings show that treatment with the taxaneDTX in the absence of cancer and other anti-cancer treatments causes cognitive impairment in healthy rodents.
Authors: Robson da Costa; Giselle F Passos; Nara L M Quintão; Elizabeth S Fernandes; João Raphael L C B Maia; Maria Martha Campos; João B Calixto Journal: Br J Pharmacol Date: 2020-06-03 Impact factor: 8.739
Authors: M Lange; F Joly; J Vardy; T Ahles; M Dubois; L Tron; G Winocur; M B De Ruiter; H Castel Journal: Ann Oncol Date: 2019-12-01 Impact factor: 32.976
Authors: Munjal M Acharya; Vahan Martirosian; Nicole N Chmielewski; Nevine Hanna; Katherine K Tran; Alicia C Liao; Lori-Ann Christie; Vipan K Parihar; Charles L Limoli Journal: Cancer Res Date: 2015-02-15 Impact factor: 12.701
Authors: Giovana R Onzi; Nathalia D'Agustini; Solange C Garcia; Silvia S Guterres; Paula R Pohlmann; Daniela D Rosa; Adriana R Pohlmann Journal: Drug Saf Date: 2022-05-23 Impact factor: 5.606
Authors: Max Oberste; Nils Schaffrath; Katharina Schmidt; Wilhelm Bloch; Elke Jäger; Karen Steindorf; Philipp Hartig; Niklas Joisten; Philipp Zimmer Journal: BMC Cancer Date: 2018-11-06 Impact factor: 4.430